Scholarlink

Background <p>Most colorectal cancers (CRC) are microsatellite stable (MSS) and show little benefit from single-agent immune checkpoint inhibition (ICI). A rapidly expanding body of work now focuses on combination strategies to remodel the tumor microenvironment (TME) and convert immune-“cold” MSS disease into an immune-responsive state. </p> Main body <p>We synthesize (i) biological liabilities that underpin MSS immune resistance; (ii) clinical evidence across key combination classes—anti-angiogenic/VEGFR + ICI (randomized AtezoTRIBE suggests a progression-free survival benefit when atezolizumab is added to FOLFOXIRI + bevacizumab), multikinase TKI + PD-1/PD-L1 (mixed activity and geographic/site heterogeneity; LEAP-017 was negative for overall survival), dual-checkpoint or next-generation CTLA-4 backbones (phase-1 botensilimab + balstilimab with durable responses in heavily pretreated MSS mCRC), EGFR- or HER2-targeted plus ICI (signals in molecularly defined subsets; e.g., CAVE rechallenge), and RT/ablation + ICI (biologically compelling but heterogeneous outcomes in pMMR-dominant settings). We emphasize biomarker-anchored selection—topology of disease (especially active liver metastases), inflammatory gene programs, and ctDNA kinetics—and propose peri-operative/oligometastatic integration frameworks relevant to surgical teams. Conclusions: Converting MSS CRC from cold to hot appears feasible in biologically selected contexts and with rational sequences. The next wave should stratify by liver involvement, embed ctDNA-anchored endpoints, and leverage surgery-embedded window studies to verify on-treatment immune conditioning.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Nan Yao,
  • Wenqiang Li,
  • Ning Duan,
  • Fuzhou Han,
  • Guoyong Yu,
  • Jun Qu

摘要

Background

Most colorectal cancers (CRC) are microsatellite stable (MSS) and show little benefit from single-agent immune checkpoint inhibition (ICI). A rapidly expanding body of work now focuses on combination strategies to remodel the tumor microenvironment (TME) and convert immune-“cold” MSS disease into an immune-responsive state.

Main body

We synthesize (i) biological liabilities that underpin MSS immune resistance; (ii) clinical evidence across key combination classes—anti-angiogenic/VEGFR + ICI (randomized AtezoTRIBE suggests a progression-free survival benefit when atezolizumab is added to FOLFOXIRI + bevacizumab), multikinase TKI + PD-1/PD-L1 (mixed activity and geographic/site heterogeneity; LEAP-017 was negative for overall survival), dual-checkpoint or next-generation CTLA-4 backbones (phase-1 botensilimab + balstilimab with durable responses in heavily pretreated MSS mCRC), EGFR- or HER2-targeted plus ICI (signals in molecularly defined subsets; e.g., CAVE rechallenge), and RT/ablation + ICI (biologically compelling but heterogeneous outcomes in pMMR-dominant settings). We emphasize biomarker-anchored selection—topology of disease (especially active liver metastases), inflammatory gene programs, and ctDNA kinetics—and propose peri-operative/oligometastatic integration frameworks relevant to surgical teams. Conclusions: Converting MSS CRC from cold to hot appears feasible in biologically selected contexts and with rational sequences. The next wave should stratify by liver involvement, embed ctDNA-anchored endpoints, and leverage surgery-embedded window studies to verify on-treatment immune conditioning.